Evelo Biosciences, Inc. (EVLO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -101.23 Million | -96.72 Million | -73.06 Million | -71.98 Million | -47.27 Million | -23.26 Million |
| Net Income | -114.52 Million | -122.17 Million | -93.66 Million | -85.47 Million | -56.94 Million | -28.04 Million |
| Depreciation & Amortization | 2.06 Million | 2.21 Million | 2.02 Million | 1.76 Million | 1.93 Million | 834 Thousand |
| Deferred income taxes | - | 3.21 Million | -6000.00 | -166 Thousand | 406 Thousand | 301 Thousand |
| Stock-based compensation | 15.15 Thousand | 15.84 Million | 8.46 Million | 8.16 Million | 6.05 Million | 1.54 Million |
| Change in working capital | -9.66 Million | 2.06 Million | 7.76 Million | 3.47 Million | 1.16 Million | 2.07 Million |
| Other non-cash items | 5.74 Million | 2.1 Million | 2.35 Million | 255 Thousand | 103 Thousand | 35 Thousand |
| Investing Cash Flow | -622 Thousand | -1.48 Million | -1.31 Million | 51.97 Million | -60.12 Million | -1.74 Million |
| Investments in PPE | -622 Thousand | -1.51 Million | -1.32 Million | -3.03 Million | -5.46 Million | -1.74 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | -136.08 Million | - |
| Sales/Maturities of investments | - | - | - | 55 Million | 81.25 Million | - |
| Other Investing Activities | - | 38 Thousand | 6000.00 | 2000.00 | 171 Thousand | - |
| Financing Cash Flow | 81.65 Million | 97.54 Million | 65.46 Million | 4.99 Million | 162.01 Million | 48.96 Million |
| Debt repayment | -47.61 Million | -14.77 Million | -10 Million | -15 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 84.54 Million | 81.75 Million | 54.99 Million | - | 75.82 Million | - |
| Other Financing Activities | 44.72 Million | 15.78 Million | 10.47 Million | 19.99 Million | 86.18 Million | 48.96 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 170 Thousand | 159 Thousand | 837 Thousand | -585 Thousand | -221 Thousand | 774 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -9.83 Million | 1.9 Million | 6.92 Million | 4.05 Million | 1.38 Million | 1.29 Million |
| Cash at beginning of period | 69.75 Million | 70.42 Million | 79.33 Million | 94.35 Million | 39.74 Million | 15.78 Million |
| Cash at end of period | 49.09 Million | 69.75 Million | 70.42 Million | 79.33 Million | 94.35 Million | 39.74 Million |
| Capital Expenditure | -622 Thousand | -1.51 Million | -1.32 Million | -3.03 Million | -5.46 Million | -1.74 Million |
| Effect of forex changes on cash | -454 Thousand | - | - | - | - | - |
| Net cash flow / Change in cash | -20.65 Million | -666 Thousand | -8.91 Million | -15.01 Million | 54.6 Million | 23.96 Million |
| Free Cash Flow | -101.85 Million | -98.24 Million | -74.38 Million | -75.01 Million | -52.74 Million | -25 Million |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -12.36 Million | -21.1 Million | -25.34 Million | -23.54 Million | -114.52 Million | -30.56 Million |
| Depreciation & Amortization | 169 Thousand | 424 Thousand | 445 Thousand | 523 Thousand | 2.06 Million | 487 Thousand |
| Deferred income taxes | 852 Thousand | 1.64 Million | - | - | - | - |
| Stock-based compensation | 2.47 Million | 2.36 Million | 2.9 Million | 3.42 Million | 15.15 Million | 3.46 Million |
| Change in working capital | -3.49 Million | -4.02 Million | 1.45 Million | -5.72 Million | -9.66 Million | 1.76 Million |
| Other non-cash items | 1.95 Million | 866 Thousand | 256 Thousand | 2.13 Million | 5.74 Million | 1.25 Million |
| Investing Cash Flow | 513 Thousand | -12 Thousand | -12 Thousand | -228 Thousand | -622 Thousand | -9000.00 |
| Investments in PPE | -47 Thousand | - | -12 Thousand | -228 Thousand | -622 Thousand | -9000.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 560 Thousand | -12 Thousand | - | - | - | - |
| Financing Cash Flow | 19.22 Million | -199 Thousand | -199 Thousand | 1.73 Million | 81.65 Million | 665 Thousand |
| Debt repayment | - | - | - | -47.61 Million | -47.61 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 24.3 Million | - | -235 Thousand | 4.86 Million | 84.54 Million | 590 Thousand |
| Other Financing Activities | -5.08 Million | -199 Thousand | 36 Thousand | 44.48 Million | 44.72 Million | 665.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -3.23 Million | 2.23 Million | -256 Thousand | 210 Thousand | 170 Thousand | -676 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -255 Thousand | -6.26 Million | 256 Thousand | -5.93 Million | -9.83 Million | - |
| Cash at beginning of period | 8.78 Million | 28.62 Million | 49.09 Million | 70.2 Million | 69.75 Million | 93.16 Million |
| Cash at end of period | 18.05 Million | 8.78 Million | 28.62 Million | 49.09 Million | 49.09 Million | 70.2 Million |
| Capital Expenditure | -47 Thousand | - | -12 Thousand | -228 Thousand | -622 Thousand | -9000.00 |
| Effect of forex changes on cash | -49 Thousand | -18 Thousand | 17 Thousand | 568 Thousand | -454 Thousand | -1.02 Million |
| Net cash flow / Change in cash | 9.27 Million | -19.84 Million | -20.47 Million | -21.11 Million | -20.65 Million | -22.95 Million |
| Free Cash Flow | -10.45 Million | -19.82 Million | -20.28 Million | -23.41 Million | -101.85 Million | -22.59 Million |
601003
GRVO
BGRIM
202A
4275
IEX